QNRX (48) KPTI (47) PBM (61) COCP (42) ⌘ Pro Terminal →

Seres Therapeutics Inc. (MCRB) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell MCRB stock right now?

Seres Therapeutics Inc. (MCRB) currently earns a Roarable Rating of D+ (Sell — SELL) with 54/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

Q: What is MCRB's 12-month price target and RQD AI Jury consensus?

MCRB's 12-month base price target is $1.91 (range $1.49 to $31.48), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$1.95 +8.94% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.98

Seres Therapeutics Inc. (MCRB) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $19.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.98 (+1.42%)🧬 Cannibal Buyback (-0.68% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 86.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-2.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MCRB)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (54/100 Composite)

🔍 WHY MCRB SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (22% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality8/20 pts (-12 pt drag)

Capital intensity & 0% operating margin leave 12 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$2.71-9.2% Next Q

Q2 (-2Q)

Grade C$2.46-15% Next Q

Q3 (-1Q)

Grade C$2.09-6.7% Next Q

Current

Grade D+$1.95-0.7% Hist 90D α

Trajectory: C+ (62) → D+ (54)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MCRB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MCRB currently carries a cautious 54/100 (D+) rating due to Cash Engine Quality (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.62) and Max Pain ($2.05) forces dealer call-delta covering toward $31.48.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-0.68% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MCRB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MCRB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 54%NO 46%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

20.930 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

5 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $2$1.95H: $30

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 22 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C-RQD 24 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on MCRB

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-35.0% ROIC with 42.0% gross margin and 4.42% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (55)

22/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like MCRB

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MCRB)

✓Walkthrough of MCRB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MCRB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -73.54%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.92H $1.95L $1.75C $1.95VOL 120.1K

RES: $3.76SUP: $1.56SMA50: $3.62SMA200: $7.11

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MCRB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MCRB Butterfly Map → + Track MCRB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MCRB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MCRB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MCRB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MCRB)

Health Care Rank #296 of 1016 ⚔️ QNRX vs MCRB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MCRB vs. QNRX, KPTI, PBM, COCP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Seres Therapeutics Inc. (MCRB) ranks #296 by composite RQD confidence (54/100, grade D+) and #836 by equity capitalization ($19.6M). Within this direct 5-issuer industry benchmark cohort, MCRB leads on earnings valuation at N/A trailing P/E, while MCRB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PBM currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with MCRB at 54/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MCRB ACTIVE Seres Therapeutics Inc.	D+	54/100	—	—	-35.0%	+8.94%	$19.6M	Benchmark Subject
QNRX Quoin Pharmaceuticals Ltd.	D	48/100	—	—	-35.0%	+0.97%	$19.9M	/qnrx-vs-mcrb →
KPTI Karyopharm Therapeutics Inc.	D	47/100	—	—	-35.0%	+5.73%	$20.0M	/kpti-vs-mcrb →
PBM Psyence Biomedical Ltd.	C-	61/100	—	—	—	+6.18%	$19.2M	/pbm-vs-mcrb →
COCP Cocrystal Pharma Inc.	D-	42/100	—	—	-35.0%	-1.01%	$18.9M	/cocp-vs-mcrb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001609809

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Seres Therapeutics Inc. (MCRB) reported GAAP revenue of $789.0K (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $5.7M, operating cash flow of $1.1M, and free cash flow of $865.0K (+100.6% YoY). On the balance sheet, MCRB closed FY2025 with $138.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$789.0K	$5.7M	$1.1M	$865.0K	$138.2M	—
FY2024 (FY)	2024-12-31	$0	$136.0K	-$148.6M	-$149.0M	$139.8M	—
FY2023 (FY)	2023-12-31	$0	-$113.7M	-$117.4M	-$117.4M	—	—

3. MCRB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MCRB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Seres Therapeutics Inc. (NASDAQ: MCRB) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $1.95 (+8.94% 1D, market cap $19.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, MCRB ranks #296 in composite RQD confidence.

How does MCRB compare to QNRX and KPTI in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MCRB carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, QNRX (Quoin Pharmaceuticals Ltd.) holds a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $19.9M) and KPTI (Karyopharm Therapeutics Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $20.0M). Among the 5-stock peer group, MCRB leads on earnings multiple (N/A) while MCRB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MCRB?

Per MCRB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001609809), Seres Therapeutics Inc. generated $789.0K in revenue, $5.7M in net income, and $865.0K in free cash flow against $138.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MCRB trading relative to its 50-day, 200-day, and 52-week technical levels?

MCRB last traded at $1.95 (+8.94% on volume of 78,506 shares), positioning the stock -46.13% below its 50-day simple moving average ($3.62) and -72.57% below its 200-day simple moving average ($7.11). Across its 52-week range of $1.68 to $29.98, MCRB sits at the 1.0% percentile with a 14-day RSI of 20.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.71 to $2.19).

MCRB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell MCRB stock right now?

Seres Therapeutics Inc. (MCRB) currently earns a Roarable Rating of D+ (Sell — SELL) with 54/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is MCRB's 12-month price target and RQD AI Jury consensus?

MCRB's 12-month base price target is $1.91 (range $1.49 to $31.48), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: MCRB RQD Cockpit MCRB 12M Forecast MCRB Earnings & Move MCRB Dividends & DRIP MCRB Insiders & 13F MCRB Whale Options MCRB Profit Sankey MCRB News & Why